Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)

NCT02152956 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT02152956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02152956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Lead sponsor
MacroGenics
Phase
Phase 1/2
Overall status
Terminated
Start date
June 9, 2014
Completion date
July 5, 2022
Enrollment
244 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

aml